8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Mar 13, 2026·SEC
Xenetic Biosciences, Inc.(XBIO)Earnings, Financials & Key Ratios
XBIO•NASDAQ
$2.89
Price updated Jul 7, 2026
AboutXenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.Show more
- Revenue$3M+19.0%
- EBITDA-$3M+30.0%
- Net Income-$3M+32.3%
- EPS (Diluted)-1.58+38.5%
- Gross Margin100%
- EBITDA Margin-95.23%+41.2%
- Operating Margin-95.23%+43.4%
- Net Margin-90.07%+43.1%
- ROE-40%+20.2%
XBIO Price & Volume
Xenetic Biosciences, Inc. (XBIO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Royalty Revenue Fails Clinical Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Limited Cash Runway
Key Thesis Takeaways
- Xenetic Biosciences operates an asset-light licensing model that generates 100% gross margins but remains fundamentally constrained by a lack of operating leverage.
- The company's reliance on volatile royalty streams to fund R&D has resulted in a $200.3 million accumulated deficit, suggesting that long-term viability depends on achieving significant clinical milestones.
- Investors should monitor the narrowing cash runway, as the current $7.3 million cash position continues to be eroded by recurring operating losses.
Verdict Logic
the company's inability to achieve operating leverage, evidenced by a -62.2% operating margin in 2026Q1, suggests that the current cash burn rate poses a significant risk to shareholder equity.
XBIO Growth Metrics
Xenetic Biosciences, Inc. (XBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years46.78%
3 Years20.36%
TTM23.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.32%
Return on Capital
10 Years-77.67%
5 Years-42.7%
3 Years-44.68%
Last Year-42.3%
XBIO Recent Earnings
Xenetic Biosciences, Inc. (XBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (82%)●Beat Revenue 7/12 qtrs (64%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.20
—
Rev
$806,923
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.22+57.7%
$0.52
Rev
$766,296+11.1%
$690,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.33+32.7%
$0.49
Rev
$1M+63.0%
$630,000
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.45+29.7%
$0.64
Rev
$589,897+23.2%
$479,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.20 | $806,923 |
| Q2 2026 | Mar 12, 2026 | $0.22vs $0.52+57.7% | $766,296vs $690,000+11.1% |
| Q4 2025 | Nov 12, 2025 | $0.33vs $0.49+32.7% | $1Mvs $630,000+63.0% |
| Q3 2025 | Aug 12, 2025 | $0.45vs $0.64+29.7% | $589,897vs $479,000+23.2% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Xenetic Biosciences, Inc. (XBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.89 | $5.46M | -1.83 | 19.04% | -90.07% | -40% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $9.21 | $2.13B | 15.35 | 19.63% | 32.43% | 38.97% | — | |
| $15.36 | $151.58M | -2.46 | — | — | -220.75% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $5.29 | $10.32M | -0.46 | -13.43% | -299.66% | — | — |
Compare XBIO vs Peers
Xenetic Biosciences, Inc. (XBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XBIO SEC Filings & Documents
Xenetic Biosciences, Inc. (XBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XBIO Frequently Asked Questions
Xenetic Biosciences, Inc. (XBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Xenetic Biosciences, Inc.'s revenue?
Xenetic Biosciences, Inc. (XBIO) reported $3.2M in revenue for fiscal year 2025. This represents a 987% increase from $0.3M in 2012.
How fast is Xenetic Biosciences, Inc. growing?
Xenetic Biosciences, Inc. (XBIO) grew revenue by 19.0% over the past year. This is strong growth.
Is XBIO profitable?
Xenetic Biosciences, Inc. (XBIO) reported a net loss of $2.2M for fiscal year 2025.
Dividend & Returns
What is XBIO's return on equity?
Xenetic Biosciences, Inc. (XBIO) has a return on equity (ROE) of -40.0%. Negative ROE indicates the company is unprofitable.
What is Xenetic Biosciences, Inc.'s free cash flow?
Xenetic Biosciences, Inc. (XBIO) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.